AQR Capital Management
NRIX icon

AQR Capital Management’s Nurix Therapeutics NRIX Stock Holding History

AQR Capital Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.35M Buy
179,464
+163,058
+994% +$2.78M ﹤0.01% 2091
2026
Q1 		$254K Buy
+16,406
New +$272K ﹤0.01% 3490
2025
Q2 		– Sell
-11,668
Closed -$139K – 3357
2025
Q1 		$139K Sell
11,668
-59,193
-84% -$990K ﹤0.01% 2956
2024
Q4 		$1.34M Buy
70,861
+23,941
+51% +$549K ﹤0.01% 1733
2024
Q3 		$1.05M Buy
46,920
+25,624
+120% +$580K ﹤0.01% 1822
2024
Q2 		$444K Buy
21,296
+9,254
+77% +$144K ﹤0.01% 2098
2024
Q1 		$177K Sell
12,042
-15,414
-56% -$166K ﹤0.01% 2272
2023
Q4 		$283K Buy
+27,456
New +$188K ﹤0.01% 2083

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management's NRIX Position: Q2 2026 in Review

AQR Capital Management increased its Nurix Therapeutics (NRIX) stake by 994% in Q2 2026, buying an estimated $2.78M and bringing the position to 179,464 shares worth $4.35M. The position accounts for ﹤0.01% of the portfolio, ranked #2091.

AQR Capital Management first reported a position in NRIX in Q4 2023 and has held it in 8 quarters since. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • AQR Capital Management held 179,464 shares of Nurix Therapeutics worth $4.35M as of Q2 2026.
  • AQR Capital Management bought 163,058 Nurix Therapeutics shares in Q2 2026, an estimated $2.78M.
  • Nurix Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #2091 holding.
  • AQR Capital Management first reported a position in Nurix Therapeutics in Q4 2023 and has held it in 8 quarters since.
  • 212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.